Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. It is grouped under the following drug class(es): Antineoplastic agents. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Faslodex, Celvestrant and ICI-182780. Its PubChem CID is 104741.
Fulvestrant
| CAS No | 129453-61-8 |
|---|---|
| Molecular Formula | C32H47F5O3S |
| Molecular Weight | 606.77 g/mol |
| Synonyms | (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy.
The listed CAS number is 129453-61-8.
The listed molecular formula is C32H47F5O3S.
The listed molecular weight is 606.77 g/mol.
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol.
The source lists Faslodex, Celvestrant and ICI-182780.